# EDGAR Filing Document

**Accession Number:** 0001671284
**File Stem:** 0001104659-25-095898
**Filing Date:** 2025-10
**Character Count:** 74179
**Document Hash:** 9c9860b0889f5bf44838ac52ff6133e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-095898.hdr.sgml**: 20251002

**ACCESSION NUMBER**: 0001104659-25-095898

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250926

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Completion of Acquisition or Disposition of Assets

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Changes in Control of Registrant

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251002

**DATE AS OF CHANGE**: 20251002

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeueHealth, Inc.
- **CENTRAL INDEX KEY:** 0001671284
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 474991296
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40537
- **FILM NUMBER:** 251367198

**BUSINESS ADDRESS:**
- **STREET 1:** 9250 NW 36TH STREET
- **STREET 2:** SUITE 420
- **CITY:** DORAL
- **STATE:** FL
- **ZIP:** 33178
- **BUSINESS PHONE:** 612-238-1321

**MAIL ADDRESS:**
- **STREET 1:** 9250 NW 36TH STREET
- **STREET 2:** SUITE 420
- **CITY:** DORAL
- **STATE:** FL
- **ZIP:** 33178

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bright Health Group Inc.
- **DATE OF NAME CHANGE:** 20210309

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bright Health Inc.
- **DATE OF NAME CHANGE:** 20160404

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) September 26, 2025

**NeueHealth, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40537** | **47-4991296** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **9250 NW 36th St Suite 420, Doral, Florida** | **33178** |
| Address of Principal Executive Office | (Zip Code) |

---

**(612) 238-1321**

Registrant's telephone number, including area code

**Not Applicable**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $0.0001 per share** | **NEUE** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**Introduction**

As previously disclosed, on December 23, 2024, NeueHealth, Inc., a Delaware corporation (the "<u>Company</u>"), entered into an Agreement and Plan of Merger (the "<u>Merger Agreement</u>") with NH Holdings 2025, Inc., a Delaware corporation ("<u>Parent</u>"), and NH Holdings Acquisition 2025, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("<u>Merger Sub</u>"). On October 2, 2025 (the "<u>Closing Date</u>"), upon the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the applicable provisions of the Delaware General Corporation Law (the "<u>DGCL</u>"), Merger Sub merged with and into the Company (the "<u>Merger</u>"), with the Company surviving such merger as a wholly owned subsidiary of Parent (the "<u>Surviving Corporation</u>"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc. ("<u>NEA</u>"). Capitalized terms used herein but not otherwise defined have the meaning set forth in the Merger Agreement.

**Item 1.01 Entry into a Material Definitive Agreement.**

On September 26, 2025, the Company entered into the Second Amendment (the "<u>Second Amendment</u>") to its Loan and Security Agreement, dated June 21, 2024 (as amended, supplemented or otherwise modified from time to time, the "<u>Loan Agreement</u>"), by and among the Company, the other Loan Parties party thereto, the lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent.

Pursuant to the Second Amendment, the Company and the lenders agreed to, among other things, modify and extend loan funding milestones and availability period of existing loan commitments, increase the minimum cash covenant level from $15.0 million to $25.0 million with two step-downs at $20.0 million and $15.0 million subject to achievement of certain milestones, and amend the definition of "Adjusted EBITDA" to add back certain specified costs, expenses and payments.

Concurrent with the closing of the Second Amendment, the lenders funded tranche 2A term loans to the Company in an aggregate principal amount of $25.0 million. In addition, while the loan commitments have been reallocated to different tranches, the aggregate principal amount of loans and commitments under the facility has not changed and the Company continues to have up to $95.0 million of loan commitments remaining under the facility, consisting of (x) tranche 2B loan commitments in an aggregate principal amount of $10.0 million, available through December 15, 2025, (y) tranche 3 loan commitments in an aggregate principal amount of $35.0 million, available from December 16, 2025 through September 30, 2026, and (z) tranche 4 loan commitments in an aggregate principal amount of up to $50.0 million, available until June 1, 2027, in each case subject to certain conditions and milestones.

The foregoing description of the Second Amendment does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Second Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 2.01. Completion of Acquisition or Disposition of Assets.**

The information set forth in the Introduction and in Items 3.03, 5.01 and 5.02 of this Current Report on Form 8-K is incorporated by reference in this Item 2.01.

***Closing of the Merger***

On the Closing Date, Parent completed the acquisition of the Company. Pursuant to the Merger Agreement, at the time at which the Merger became effective (the "<u>Effective Time</u>"), each share of common stock, par value $0.0001 per share, of the Company ("<u>Company Common Stock</u>") that was issued and outstanding as of immediately prior to the Effective Time (other than shares owned immediately prior to the Effective Time by the Company, NH Holdings 2025 SPV, L.P. ("<u>Ultimate Parent</u>"), Parent, Merger Sub or any of their respective subsidiaries (including shares contributed to Ultimate Parent prior to the Effective Time pursuant to rollover agreements or other similar agreements), which were canceled for no consideration, and shares of Company Common Stock held by stockholders who properly and validly exercised their statutory rights of appraisal in respect of such shares in accordance with Section 262 of the DGCL) was canceled and extinguished and automatically converted into the right to receive cash in an amount equal to $7.33 per share, payable to the holder thereof, without interest thereon and less any applicable withholding taxes.

In connection with the Merger, certain stockholders of the Company, including (i) the holders of all of the shares of Series A Convertible Perpetual Preferred Stock, par value $0.0001 per share ("<u>Series A Preferred Stock"</u>), (ii) the holders of all of the shares of Series B Convertible Perpetual Preferred Stock, par value $0.0001 per share ("<u>Series B Preferred Stock</u>" and, together with Series A Preferred Stock, "<u>Company Preferred Stock</u>"), (iii) the holders of all warrants to purchase shares of Company Common Stock ("<u>Company Warrants</u>") and (iv) certain holders of Company Common Stock (the "<u>Rollover Holders</u>"), entered into rollover agreements with Ultimate Parent, Parent and Merger Sub, pursuant to which, among other things and on the terms and subject to the conditions set forth therein, the Rollover Holders contributed all of their shares of Company Common Stock, Series A Preferred Stock, Series B Preferred Stock and Company Warrants, as applicable, to Ultimate Parent immediately prior to the Effective Time in exchange for the issuance to the Rollover Holders of limited partnership interests in Ultimate Parent.

In addition, pursuant to the Merger Agreement, at the Effective Time:

&nbsp;&nbsp;&nbsp;&nbsp;· Each option to purchase shares of Company Common
Stock, whether vested or unvested, that had a per share exercise price less than the Per Share Merger Consideration was automatically
canceled and terminated and converted into the right to receive an amount in cash equal to the product of (i) the excess of the Per
Share Merger Consideration over the applicable per share exercise price of such option, multiplied by (ii) the total number of shares
of Company Common Stock subject to such option immediately prior to the Effective Time.

&nbsp;&nbsp;&nbsp;&nbsp;· Each option to purchase shares of Company Common
Stock, whether vested or unvested, that had a per share exercise price equal to or greater than the Per Share Merger Consideration was
canceled and terminated for no consideration.

&nbsp;&nbsp;&nbsp;&nbsp;· Each restricted stock unit of the Company with
respect to shares of Company Common Stock that was subject solely to service-based vesting requirements (and not performance-based vesting
requirements) (each, a " <u>Company RSU</u> ") was assumed by Parent and adjusted into a restricted stock unit of Parent with
respect to a number of shares of common stock of Parent equal to the number of shares of Company Common Stock subject to such Company
RSU and otherwise having the same vesting and other terms and conditions as such Company RSU.

&nbsp;&nbsp;&nbsp;&nbsp;· Each restricted stock unit of the Company with
respect to shares of Company Common Stock that was subject to performance-based vesting requirements was canceled and terminated for no
consideration.

The foregoing description of the Merger and the Merger Agreement, and the transactions contemplated thereby, does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement, a copy of which was filed as [Exhibit 2.1](https://www.sec.gov/Archives/edgar/data/1671284/000110465924131382/tm2431820d1_ex2-1.htm) to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "<u>SEC</u>") on December 23, 2024, and which is incorporated by reference herein.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference in this Item 2.03.

**Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

The information set forth in the Introduction and Item 2.01 of this Current Report on Form 8-K is incorporated by reference in this Item 3.01.

In connection with the closing of the Merger, the Company notified the New York Stock Exchange ("<u>NYSE</u>") of its intent to remove the Company Common Stock from listing on the NYSE and requested that the NYSE (i) suspend trading of the Company Common Stock on the NYSE prior to the opening of trading on October 2, 2025 and (ii) file a Notification of Removal from Listing and/or Registration on Form 25 with the SEC to delist the Company Common Stock from NYSE and deregister the Company Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>").

Upon effectiveness of the Form 25, the Company intends to file with the SEC a Form 15 under the Exchange Act requesting the deregistration of the Company's securities under Section 12(g) of the Exchange Act and the suspension of the Company's reporting obligations under Sections 13 and 15(d) of the Exchange Act.

**Item 3.02 Unregistered Sales of Equity Securities.**

On the Closing Date, the Company and NEA 18 Venture Growth Equity, L.P., New Enterprise Associates 15, L.P., New Enterprise Associates 16, L.P. and New Enterprise Associates 17, L.P. (collectively, the "<u>Holders</u>") entered into a warrantholders agreement (the "<u>Warrant Agreement</u>") pursuant to which the Company issued warrants ("<u>Warrants</u>") representing the Holders' right to purchase 1,116,765 shares of Company Common Stock at an exercise price of $0.01 per share.

Under the Warrant Agreement, the Warrants were issued in a private placement in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), provided by Section 4(a)(2) of the Securities Act.

**Item 3.03. Material Modification to Rights of Security Holders.**

The information set forth in the Introduction, Item 2.01, Item 3.01 and Item 5.02 of this Current Report on Form 8-K is incorporated by reference in this Item 3.03.

**Item 5.01. Change in Control of the Registrant.**

The information set forth in the Introduction and in Item 2.01 of this Current Report on Form 8-K is incorporated by reference in this Item 5.01.

As a result of the completion of the Merger, a change in control of the Company occurred, and the Company became a wholly owned subsidiary of Parent. The aggregate merger consideration paid to Company stockholders was approximately $22.3 million. The funds used by Parent to consummate the Merger and complete the related transactions came from an increase in the Company's existing subordinated credit facility with NEA and the lenders from time to time party thereto.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

The information set forth in the Introduction and in Item 2.01 of this Current Report on Form 8-K is incorporated by reference in this Item 5.02.

At the closing of the Merger, Kedrick D. Adkins Jr., Linda Gooden, Jeffrey R. Immelt, Manuel Kadre, Stephen Kraus, Mohamad Makhzoumi, G. Mike Mikan, Andrew Slavitt, Robert J. Sheehy and Matthew G. Manders, members of the board of directors of the Company, ceased to be directors of the Company. In accordance with the terms of the Merger Agreement, at the Effective Time, the directors of Merger Sub, Jeffrey R. Immelt, Manuel Kadre, Stephen Kraus, Mohamad Makhzoumi, G. Mike Mikan, Andrew Slavitt, Robert J. Sheehy, Matthew G. Manders and Blake Wu, became the directors of the Surviving Corporation.

In accordance with the terms of the Merger Agreement, at the Effective Time, the officers of the Company, including G. Mike Mikan, Jay Matushak, Tomas Orozco, Jeffrey J. Scherman and Jeffery M. Craig, became the officers of the Surviving Corporation.

**Item 7.01. Regulation FD Disclosure.**

On October 2, 2025, the Company and Parent issued a joint press release announcing the closing of the Merger. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, shall not otherwise be subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act, unless specifically identified therein as being incorporated therein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit <br> No.** | **Description** |
| [2.1\*](https://www.sec.gov/Archives/edgar/data/1671284/000110465924131382/tm2431820d1_ex2-1.htm) | [Agreement and Plan of Merger, dated as of December 23, 2024, by and among NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and NeueHealth, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by NeueHealth, Inc. on December 23, 2024).](https://www.sec.gov/Archives/edgar/data/1671284/000110465924131382/tm2431820d1_ex2-1.htm) |
| [10.1^](tm2527826d2_ex10-1.htm) | [Second Amendment to Loan and Security Agreement, dated September 26, 2025, by and among NeueHealth, Inc., the other Loan Parties party thereto, the lenders party thereto and Hercules Capital, Inc., as administrative agent and collateral agent.](tm2527826d2_ex10-1.htm) |
| [99.1](tm2527826d2_ex99-1.htm) | [Press Release, dated as of October 2, 2025.](tm2527826d2_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document). |

---

\* Certain schedules (or similar attachments) have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule (or similar attachment) to the SEC upon request.

^ Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule (or similar attachment) to the SEC upon request.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | NeueHealth, Inc. | NeueHealth, Inc. |
| Date: | October 2, 2025 | By: | /s/ Jeff Craig |
|  |  | Name: | Jeff Craig |
|  |  | Title: | General Counsel and Corporate Secretary |

---

## Exhibit 10.1

**Exhibit 10.1**

**SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT**

This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this "<u>Amendment</u>"), dated as of September 26, 2025, is entered into by and among NEUEHEALTH, INC., a Delaware corporation ("<u>Company</u>"), each other Borrower party hereto, each Guarantor party hereto (together with Company and each Borrower party hereto, collectively, the "<u>Loan Parties</u>"), the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as the "<u>Lenders</u>"), and HERCULES CAPITAL, INC., a Maryland corporation, in its capacity as administrative agent and collateral agent for itself and the Lenders (together with its successors and assigns, in such capacity, the "<u>Agent</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The Loan Parties, the Lenders and the Agent are parties to that certain Loan and Security Agreement, dated as of June 21, 2024 (and amended, restated, supplemented or otherwise modified from time to time prior to the date of this Amendment, including by way of that certain First Amendment to Loan and Security Agreement dated as of September 12, 2025, the "<u>Loan Agreement</u>"). The Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. The Loan Parties, the Agent and the Lenders have agreed to certain amendments to the Loan Agreement, upon the terms and conditions more fully set forth herein.

**SECTION 1 Definitions; Interpretation.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Terms Defined in Loan Agreement**. All capitalized terms used in this Amendment (including in the recitals hereof) and not otherwise defined herein shall have the meanings assigned to them in the Loan Agreement (as amended by this Amendment).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Rules of Construction**. The rules of construction in the final paragraph of Section 1.1 of the Loan Agreement shall be applicable to this Amendment and are incorporated herein by this reference.

**SECTION 2 Amendments to the Loan Agreement.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon the occurrence of the Second Amendment Effective Date, the Loan Agreement is amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>New Definitions</u>. The following defined terms are added to Section 1.1 of the Loan Agreement in proper alphabetical order:

"<u>2024 Consent</u>" means that certain Consent Under Loan and Security Agreement, dated as of October 29, 2024, by and among the Loan Parties, the Agent and the Lenders.

"<u>2025 Letter Agreement</u>" means that certain Letter Agreement, dated as of September 26, 2025, by and among the Company and the Agent.

"<u>CMS Interest Waiver Milestone Date</u>" has the meaning given to such term in the 2025 Letter Agreement.

"<u>CMS Obligation Liquidity Milestone Date</u>" has the meaning given to such term in the 2025 Letter Agreement.

"<u>Merger Closing Date</u>" has the meaning given to the term "Closing Date" in the Merger Agreement.

"<u>Merger Guarantors</u>" has the meaning given to the term "Guarantors" in the Merger Agreement.

"<u>Minimum Cash Milestone Date</u>" means the first date on which both of the following conditions have been satisfied: (i) the Tranche 3 Milestone Date has occurred; and (ii) Borrower has achieved Adjusted EBITDA, measured as of the last day of any fiscal quarter of Company ending after the occurrence of the Tranche 3 Milestone Date and calculated for the trailing twelve (12) month period ending on such measurement date, of greater than Seventy-Five Million Dollars ($75,000,000); in each case, based upon written evidence provided to, and reviewed and approved by, the Agent in its reasonable discretion.

"<u>Second Amendment Agreement</u>" means that certain Second Amendment to Loan and Security Agreement, dated as of September 26, 2025, by and among the Loan Parties, the Agent and the Lenders.

"<u>Second Amendment Effective Date</u>" has the meaning given to such term in the Second Amendment Agreement.

"<u>Tranche 2A Advance</u>" has the meaning given to it in <u>Section 2.2(a)</u>.

"<u>Tranche 2B Advance</u>" has the meaning given to it in <u>Section 2.2(a)</u>.

"<u>Tranche 2B Availability Period</u>" means the period commencing on the Tranche 2B Milestone Date and ending on December 15, 2025. Notwithstanding the generality of the foregoing, subject to the approval by the Lenders' investment committee in its sole and absolute discretion, the Company may request to extend the Tranche 2B Availability Period to end on such later date as the Agent shall designate in writing (which may be in the form of an e-mail).

"<u>Tranche 2B Milestone Date</u>" has the meaning given to such term in the 2025 Letter Agreement.

"<u>Tranche 3 Advance</u>" has the meaning given to such term in <u>Section 2.2(a)</u>.

"<u>Undrawn Commitment</u>" means as to any Lender, the sum of (a) such Lender's undrawn Tranche 2B Commitment, if any, following the expiration of the Tranche 2B Availability Period, plus (b) such Lender's undrawn Tranche 3 Commitment, if any, following the expiration of the Tranche 3 Availability Period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>Amended Definition</u>. The following definitions in Section 1.1 of the Loan Agreement are amended and restated in its entirety as follows:

"<u>Tranche 2 Advance</u>" means a Tranche 2A Advance or a Tranche 2B Advance.

"<u>Tranche 3 Availability Period</u>" means the period commencing on the Tranche 3 Milestone Date and ending on September 30, 2026. Notwithstanding the generality of the foregoing, subject to the approval by the Lenders' investment committee in its sole and absolute discretion, the Company may request the Tranche 3 Availability Period to commence on such earlier date, or end on such later date, in each case, as the Agent shall designate in writing (which may be in the form of an e-mail).

"<u>Tranche 3 Milestone Date</u>" has the meaning given in the 2025 Letter Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Deleted Definitions</u>. The following defined terms set forth in Section 1.1 of the Loan Agreement are deleted in their entirety: "*Tranche 2 Availability Period*", "*Tranche 2 Milestone Date*", and "*Tranche 3 Advances*".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) <u>Definition of Adjusted EBITDA</u>. The definition of Adjusted EBITDA is amended by (i) deleting "minus" at the end of subsection (x) and inserting in lieu thereof "plus", and (ii) inserting new subsections (xi) and (xii), as follows:

"(xi) transaction costs and expenses relating to the Merger Agreement (and the transactions contemplated thereby) incurred prior to the date that is ninety (90) days after the Merger Closing Date (including costs and expenses incurred in periods ending prior to the Second Amendment Effective Date, which costs and expenses shall be added to Adjusted EBITDA as though such costs and expenses had been included on the first day of the relevant period), to the extent such costs and expenses have been reimbursed in cash by the Merger Guarantors; <u>plus</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) amounts recognized in accordance with GAAP in respect of payments made pursuant to the Class P Cancellation Agreements (as defined in the Centrum Sale Documents (as defined in the 2024 Consent)) relating to the Centrum Buyout (as defined in the 2024 Consent), including any portion recognized ratably over a period of time as compensation expense; provided that (A) only the portion recognized during such period (and not any future-period amount) may be added back and shall not be accelerated, (B) the amount of the payments to be made pursuant to the Class P Cancellation Agreements as of the Second Amendment Effective Date are not increased, and the timing of such payments is not accelerated, without the written consent of Agent, and (C) the aggregate amount added to Adjusted EBITDA pursuant to this clause (b)(xii) shall not exceed Fifteen Million Four Hundred Seventy-Two Thousand Dollars ($15,472,000); <u>minus</u>"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) <u>Definition of Permitted Investment</u>. The definition of Permitted Investment is amended by (i) deleting "and" at the end of subsection (xx), (ii) deleting "." appearing after subsection (xxi) and inserting in lieu thereof "; and", and (iii) inserting a new subsection (xxii) as follows:

"(xxii) Investments by a Loan Party into an escrow account maintained at City National Bank by Bright Health Management, Inc., a Delaware corporation, at City National Bank of Florida with account number ending in 1242 or such other account as approved by the Agent (the "<u>Colorado Escrow Account</u>"), which shall, for the avoidance of doubt, constitute an Excluded Account, but only for so long as (A) the aggregate amount of such Investments, and the funds deposited in the Colorado Escrow Account, does not in either case exceed Seven Million Five Hundred Thousand Dollars ($7,500,000) in the aggregate at any time during the term of this Agreement, (B) all funds deposited in the Colorado Escrow Account shall be (1) held solely for the benefit of Bright Health Insurance Company, a Colorado corporation ("<u>BHIC</u>"); and (2) withdrawn only if: (I) the sole payee is BHIC; (II) such funds are used exclusively to satisfy BHIC's payment obligations to CMS and/or HHS; and (III) such withdrawal occurs on or after the earlier of (x) the CMS Interest Waiver Milestone Date, or (y) September 1, 2026, but in any event no later than thirty (30) calendar days after the CMS Interest Waiver Milestone Date; provided that, notwithstanding the foregoing, if the Colorado Escrow Account is terminated by City National Bank of Florida in its capacity as escrow agent in accordance with its terms, then, to the extent any funds deposited in the Colorado Escrow Account are received or otherwise come under the direct control of the Company or any of its Subsidiaries (other than BHIC), such funds shall thereafter be promptly disbursed into a bank account of a Loan Party that is subject to an Account Control Agreement."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) <u>Section 2.2(a)</u>. Subclauses (a)(ii) and (a)(iii) in Section 2.2 of the Loan Agreement are amended and restated in their entirety as follows:

"(ii) <u>Tranche 2</u>. Subject to the terms and conditions of this Agreement, Borrower may request, and the Lenders shall severally (and not jointly) make, in each case:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) on or around the Second Amendment Effective Date, a Term Loan Advance in an aggregate principal amount equal to Twenty-Five Million Dollars ($25,000,000) (such Term Loan Advance, the "<u>Tranche 2A Advance</u>"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(y) during the Tranche 2B Availability Period, a Term Loan Advance in an aggregate principal amount equal to Ten Million Dollars ($10,000,000) (such Term Loan Advance, the "<u>Tranche 2B Advance</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>Tranche 3</u>. Subject to the terms and conditions of this Agreement, Borrower may request, and the Lenders shall severally (and not jointly) make, in each case, during the Tranche 3 Availability Period, a Term Loan Advance in an aggregate principal amount of up to (x) Thirty-Five Million Dollars ($35,000,000), <u>plus</u> (y) the undrawn Tranche 2B Commitment calculated on the date of such Term Loan Advance, if any, for so long as the Tranche 2B Availability Period has ended as of the date of such Term Loan Advance (such Term Loan Advance, the "<u>Tranche 3 Advance</u>")."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) <u>Section 4.2</u>. Section 4.2 of the Loan Agreement is amended by (i) deleting "and" at the end of clause (d), (ii) deleting "." appearing after clause (e) and inserting in lieu thereof "; and", and (iii) inserting a new clause (f) as follows:

"(f) With respect to any Advance (other than the Tranche 1 Advances and the Tranche 2A Advance), the Company shall, to the extent necessary to achieve the same economic result, cause NH Holdings 2025 SPV, L.P., the parent of the Company after giving effect to the transactions occurring on the Merger Closing Date, to issue to each Lender additional non-voting common units of itself (the "<u>Warrant Replacement Units</u>"), substantially equivalent in form and substance to the Warrants issued as of the Closing Date (each, a "<u>Closing Date Warrant</u>"), so as to ensure that, notwithstanding the occurrence of the Merger Closing Date and the exercise of the related Closing Date Warrant, each Lender (or its predecessor) will have the ability to receive non-voting common units of NH Holdings 2025 SPV, L.P. for the same number of shares of common stock of the Company (or its equivalent equity interest of the Company following the Merger Closing Date) as such Lender would have been entitled to exercise had the Merger Closing Date and the exercise of the related Closing Date Warrant not occurred (for avoidance of doubt, the Warrant Replacement Units will be issued in lieu of any additional shares of common stock being exercisable under Section 1(b) of the Closing Date Warrant)."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) <u>Section 7.21(a)</u>. Section 7.21(a) of the Loan Agreement is amended and restated in its entirety as follows:

"(a) <u>Minimum Cash</u>. The Loan Parties shall maintain Qualified Cash in an amount greater than or equal to (i) at all times prior to the occurrence of the Tranche 3 Milestone Date, Twenty-Five Million Dollars ($25,000,000), and (ii) at all times thereafter, Twenty Million Dollars ($20,000,000); provided that, notwithstanding the foregoing, upon the occurrence of the Minimum Cash Milestone Date, the Loan Parties shall instead maintain Qualified Cash in an amount greater than or equal to Fifteen Million Dollars ($15,000,000) at all times thereafter."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) <u>Section 7.21(c)</u>. The following new Section 7.21(c) of the Loan Agreement is inserted as follows:

"(c) <u>CMS Obligation Liquidity Milestone Date</u>. The CMS Obligation Liquidity Milestone Date shall have occurred on June 30, 2026."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) <u>Form of Compliance Certificate</u>. Exhibit E to the Loan Agreement is hereby amended and restated as set forth in Exhibit A attached hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) <u>Schedule 1.1</u>. Schedule 1.1 to the Loan Agreement is hereby amended and restated as set forth in Exhibit B attached hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) <u>Schedule 9.10(a)</u>. Schedule 9.10 to the Loan Agreement is hereby amended to add the obligations set forth in Schedule 9.10(a) to the 2025 Letter Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **References Within Loan Agreement**. Each reference in the Loan Agreement to "this Agreement" and the words "hereof," "herein," "hereunder", or words of like import, shall mean and be a reference to the Loan Agreement as amended by this Amendment. This Amendment shall be a Loan Document.

**SECTION 3 Conditions of Effectiveness**. The effectiveness of this Amendment (the "<u>Second Amendment Effective Date</u>") shall be subject to the Agent's receipt of the following documents, in form and substance satisfactory to Agent, or, as applicable, the following conditions being met:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Agent shall have received this Amendment, executed by the Agent, the Lenders and the Loan Parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Agent shall have received the Affirmation to Subordination Agreement, executed by the Agent and the "Required Lenders" (as defined in the NEA Credit Agreement);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Agent shall have received an executed copy of the 2025 Letter Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Borrower shall have submitted an Advance Request for the Tranche 2A Advance (each Lender party hereto hereby waives any applicable prior notice requirement under Section 2.2(c) of the Loan Agreement so long as the Borrower has submitted an Advance Request one (1) Business Day before the Second Amendment Effective Date);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Borrower shall have paid (i) all invoiced costs and expenses then due in accordance with <u>Section 6(d)</u>, and (ii) all other fees, costs and expenses, if any, due and payable as of the date hereof under the Loan Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the Agent shall have received good standing certificates in the State of incorporation or formation of each of the Loan Parties; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) on the Second Amendment Effective Date, immediately after giving effect to the Amendment:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the representations and warranties contained in <u>Section 5</u> shall be true and correct in all material respects on and as of the Second Amendment Effective Date as though made on and as of such date, *provided,* that to the extent such representations and warranties by their terms expressly relate only to a prior date such representations and warranties shall be true and correct as of such prior date; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) there exist no Events of Default or events that with the passage of time would result in an Event of Default; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) such other documents or evidence as the Agent may reasonably request to effectuate the terms of this Amendment.

**SECTION 4 Representations and Warranties**. To induce the Agent and the Lenders to enter into this Amendment, each Loan Party hereby confirms, as of the date hereof, (a) that the representations and warranties made by it in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in all material respects; *provided*, *however*, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; *provided, further,* that to the extent such representations and warranties by their terms expressly relate only to a prior date such representations and warranties shall be true and correct as of such prior date; (b) that no Default or Event of Default has occurred and is continuing; (c) that there has not been and there does not exist a Material Adverse Effect; (d) the agreements and obligations of Borrower contained in the Loan Documents and in this Amendment constitute the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors' rights or by the application of general principles of equity; and (e) the execution, delivery and performance of this Amendment by Borrower will not violate any law, rule, regulation, order, contractual obligation or organizational document of Borrower and will not result in, or require, the creation or imposition of any lien, claim or encumbrance of any kind on any of its properties or revenues. For the purposes of this <u>Section 4</u>, each reference in section 5 of the Loan Agreement to "this Agreement", and the words "hereof", "herein", "hereunder", or words of like import in such Section, shall mean and be a reference to the Loan Agreement as amended by this Amendment.

**SECTION 5 Release.** In consideration of the agreements of the Agent and each Lender contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Borrower, on behalf of itself and its successors, assigns, and other legal representatives, hereby to the extent possible under applicable law fully, absolutely, unconditionally and irrevocably releases, remises and forever discharges the Agent and each Lender, and its successors and assigns, and its present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (the Agent, Lenders and all such other persons being hereinafter referred to collectively as the "<u>Releasees</u>" and individually as a "<u>Releasee</u>"), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money, accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever of every name and nature, known or unknown, suspected or unsuspected, both at law and in equity, which Borrower, or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, for or on account of, or in relation to, or in any way in connection with the Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto. Borrower understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. Borrower agrees that no fact, event, circumstance, evidence or transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above.

**SECTION 6 Miscellaneous**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Loan Documents Otherwise Not Affected; Reaffirmation; No Novation**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Except as expressly amended pursuant hereto or referenced herein, the Loan Agreement and the other Loan Documents shall remain unchanged and in full force and effect and are hereby ratified and confirmed in all respects. The Lenders' and the Agent's execution and delivery of, or acceptance of, this Amendment shall not be deemed to create a course of dealing or otherwise create any express or implied duty by any of them to provide any other or further amendments, consents or waivers in the future.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Borrower hereby expressly (1) reaffirms, ratifies and confirms its Secured Obligations under the Loan Agreement and the other Loan Documents, (2) reaffirms, ratifies and confirms the grant of security under Section 3 of the Loan Agreement, (3) reaffirms, ratifies and confirms that the Agent has and shall continue to have valid, enforceable and perfected first-priority liens, subject only to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by Borrower to the Agent (for the benefit of itself and the Lenders), pursuant to the Loan Documents or otherwise granted to or held by the Agent (for the benefit of itself and the Lenders), (4) reaffirms that such grant of security in the Collateral secures all Secured Obligations under the Loan Agreement, including without limitation any Term Loan Advances funded on or after the Second Amendment Effective Date, as of the date hereof, and with effect from (and including) the Second Amendment Effective Date, such grant of security in the Collateral: (x) remains in full force and effect notwithstanding the amendments expressly referenced herein; and (y) secures all Secured Obligations under the Loan Agreement, as amended by this Amendment, and the other Loan Documents, (5) agrees that this Amendment shall be a "Loan Document" under the Loan Agreement, and (6) agrees that the Loan Agreement and each other Loan Document shall remain in full force and effect following any action contemplated in connection herewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) This Amendment is not a novation and the terms and conditions of this Amendment shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. Nothing in this Amendment is intended, or shall be construed, to constitute an accord and satisfaction of Borrower's Secured Obligations under or in connection with the Loan Agreement and any other Loan Document or to modify, affect or impair the perfection or continuity of the Agent's security interest in, (on behalf of itself and the Lender) security titles to or other liens on any Collateral for the Secured Obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Conditions**. For purposes of determining compliance with the conditions specified in <u>Section 3</u>, each Lender that has signed this Amendment shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to such Lender unless the Agent shall have received notice from such Lender prior to the date hereof specifying its objection thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **No Reliance**. Borrower hereby acknowledges and confirms to the Agent and the Lenders that Borrower is executing this Amendment on the basis of its own investigation and for its own reasons without reliance upon any agreement, representation, understanding or communication by or on behalf of any other Person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **Costs and Expenses**. Borrower agrees to pay to the Agent on the date hereof all reasonable and documented out-of-pocket costs and expenses of the Agent and each Lender party hereto, including the reasonable and documented out-of-pocket fees and disbursements of counsel to the Agent and each Lender party hereto (including allocated costs of internal counsel) in connection with the negotiation, preparation, execution and delivery of this Amendment and any other documents to be delivered in connection herewith on the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) **Binding Effect**. This Amendment binds and is for the benefit of the successors and permitted assigns of each party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) **Governing Law.** This Amendment shall be governed by, and construed and enforced in accordance with, the laws of the State of NEW YORK, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) **Complete Agreement; Amendments**. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements with respect to such subject matter. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) **Severability of Provisions.** Each provision of this Amendment is severable from every other provision in determining the enforceability of any provision.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) **Counterparts**. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Amendment. Delivery of an executed counterpart of a signature page of this Amendment by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) **Electronic Execution of Certain Other Documents**. The words "execution," "execute", "signed," "signature," and words of like import in or related to any document to be signed in connection with this Amendment and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the California Uniform Electronic Transactions Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment, as of the date first above written.

---

| | |
|:---|:---|
| COMPANY AND ORIGINAL BORROWER: | COMPANY AND ORIGINAL BORROWER: |
| NEUEHEALTH, INC. | NEUEHEALTH, INC. |
| Signature: | /s/ Jeff Craig |
| Print Name: | Jeff Craig |
| Title: | General Counsel and Corporate Secretary |

---

[Signature Page to Second Amendment to Loan and Security Agreement]

---

| | |
|:---|:---|
| BORROWERS: | BORROWERS: |
| BRIGHT HEALTH SERVICES, INC. | BRIGHT HEALTH SERVICES, INC. |
| BRIGHT HEALTH MANAGEMENT, INC. | BRIGHT HEALTH MANAGEMENT, INC. |
| MEDICAL PRACTICE HOLDING COMPANY, LLC | MEDICAL PRACTICE HOLDING COMPANY, LLC |
| NEUEHEALTH ADVANTAGE ACO, LLC | NEUEHEALTH ADVANTAGE ACO, LLC |
| NEUEHEALTH, LLC | NEUEHEALTH, LLC |
| NEUEHEALTH COMMUNITY ACO, LLC | NEUEHEALTH COMMUNITY ACO, LLC |
| Signature: | /s/ Jeff Craig |
| Print Name: | Jeff Craig |
| Title: | Secretary |
| NEUEHEALTH COLLABORATIVE CARE, LLC | NEUEHEALTH COLLABORATIVE CARE, LLC |
| NEUEHEALTH PREMIER ACO, LLC | NEUEHEALTH PREMIER ACO, LLC |
| NEUEHEALTH ACCOUNTABLE CARE, LLC | NEUEHEALTH ACCOUNTABLE CARE, LLC |
| NEUEHEALTH PARTNERS, LLC | NEUEHEALTH PARTNERS, LLC |
| NEUEHEALTH PARTNER SERVICES, LLC | NEUEHEALTH PARTNER SERVICES, LLC |
| NEUEHEALTH PARTNERS OF FLORIDA, LLC | NEUEHEALTH PARTNERS OF FLORIDA, LLC |
| NEUEHEALTH PARTNERS OF CALIFORNIA, LLC | NEUEHEALTH PARTNERS OF CALIFORNIA, LLC |
| NEUEHEALTH PARTNERS FLORIDA RBE, LLC | NEUEHEALTH PARTNERS FLORIDA RBE, LLC |
| Signature: | /s/ Jonathan Bakewicz |
| Print Name: | Jonathan Bakewicz |
| Title: | Secretary |
| BRIGHT HEALTH COMPANY OF CALIFORNIA, INC. | BRIGHT HEALTH COMPANY OF CALIFORNIA, INC. |
| Signature: | /s/ Jeff Craig |
| Print Name: | Jeff Craig |
| Title: | Secretary |

---

[Signature Page to Second Amendment to Loan and Security Agreement]

---

| | |
|:---|:---|
| CENTRUM MEDICAL HOLDINGS, LLC | CENTRUM MEDICAL HOLDINGS, LLC |
| CENTRUM MEDICAL CENTER – AIRPORT, LLC | CENTRUM MEDICAL CENTER – AIRPORT, LLC |
| CENTRUM MEDICAL CENTER – EAST HIALEAH, LLC | CENTRUM MEDICAL CENTER – EAST HIALEAH, LLC |
| CENTRUM MEDICAL CENTER – WEST HIALEAH, LLC | CENTRUM MEDICAL CENTER – WEST HIALEAH, LLC |
| CENTRUM MEDICAL CENTER – MIAMI GARDENS, LLC | CENTRUM MEDICAL CENTER – MIAMI GARDENS, LLC |
| CENTRUM MEDICAL CENTER – SOUTH DADE, LLC | CENTRUM MEDICAL CENTER – SOUTH DADE, LLC |
| CENTRUM MEDICAL CENTER – WESTCHESTER, LLC | CENTRUM MEDICAL CENTER – WESTCHESTER, LLC |
| CENTRUM MEDICAL CENTER – LITTLE HAVANA 27 AVE, LLC CENTRUM MEDICAL CENTER – LITTLE HAVANA 12 AVE, LLC CENTRUM MEDICAL CENTERS OF CORAL SPRINGS, LLC | CENTRUM MEDICAL CENTER – LITTLE HAVANA 27 AVE, LLC CENTRUM MEDICAL CENTER – LITTLE HAVANA 12 AVE, LLC CENTRUM MEDICAL CENTERS OF CORAL SPRINGS, LLC |
| CENTRUM MEDICAL CENTERS OF MARGATE, LLC | CENTRUM MEDICAL CENTERS OF MARGATE, LLC |
| CENTRUM MEDICAL CENTERS OF DAVIE, LLC | CENTRUM MEDICAL CENTERS OF DAVIE, LLC |
| CENTRUM MEDICAL CENTERS OF HALLANDALE, LLC | CENTRUM MEDICAL CENTERS OF HALLANDALE, LLC |
| CENTRUM MEDICAL CENTERS OF LIGHTHOUSE POINT, LLC CENTRUM MEDICAL CENTERS OF FORT LAUDERDALE, LLC CENTRUM MEDICAL CENTERS OF SHERIDAN, LLC | CENTRUM MEDICAL CENTERS OF LIGHTHOUSE POINT, LLC CENTRUM MEDICAL CENTERS OF FORT LAUDERDALE, LLC CENTRUM MEDICAL CENTERS OF SHERIDAN, LLC |
| CENTRUM MEDICAL CENTERS OF MIRAMAR, LLC | CENTRUM MEDICAL CENTERS OF MIRAMAR, LLC |
| CENTRUM MEDICAL CENTER – HOMESTEAD, LLC | CENTRUM MEDICAL CENTER – HOMESTEAD, LLC |
| CENTRUM MEDICAL HOLDINGS OF TEXAS, LLC | CENTRUM MEDICAL HOLDINGS OF TEXAS, LLC |
| CENTRUM PHARMACY, LLC | CENTRUM PHARMACY, LLC |
| CENTRUM SPECIALTY NETWORK, LLC | CENTRUM SPECIALTY NETWORK, LLC |
| MED CARE CENTERS, LLC | MED CARE CENTERS, LLC |
| MED CARE EXPRESS, LLC | MED CARE EXPRESS, LLC |
| MEDLIFE WELLNESS CENTERS, LLC | MEDLIFE WELLNESS CENTERS, LLC |
| CENTRUM HEALTH IP, LLC | CENTRUM HEALTH IP, LLC |
| MED PLAN CLINIC, LLC | MED PLAN CLINIC, LLC |
| MEDCARE QUALITY MEDICAL CENTERS, LLC | MEDCARE QUALITY MEDICAL CENTERS, LLC |
| Signature: | /s/ Jeff Craig |
| Print Name: | Jeff Craig |
| Title: | Secretary |

---

[Signature Page to Second Amendment to Loan and Security Agreement]

---

| | |
|:---|:---|
| GUARANTORS: | GUARANTORS: |
| NEUEHEALTH PARTNERS TEXAS RBE, LLC | NEUEHEALTH PARTNERS TEXAS RBE, LLC |
| Signature: | /s/ Jeff Craig |
| Print Name: | Jeff Craig |
| Title: | Secretary |
| NEUEHEALTH ALLIANCE, LLC | NEUEHEALTH ALLIANCE, LLC |
| NEUEHEALTH ALLIANCE II, LLC | NEUEHEALTH ALLIANCE II, LLC |
| Signature: | /s/ Carisa Schultz |
| Print Name: | Carisa Schultz |
| Title: | CFO |

---

[SIGNATURES CONTINUE ON THE NEXT PAGE]

[Signature Page to Second Amendment to Loan and Security Agreement]

---

| | |
|:---|:---|
| AGENT: | AGENT: |
| HERCULES CAPITAL, INC. | HERCULES CAPITAL, INC. |
| Signature: | /s/ Seth Meyer |
| Print Name: | Seth Meyer |
| Title: | Chief Financial Officer |

---

[Signature Page to Second Amendment to Loan and Security Agreement]

---

| | |
|:---|:---|
| LENDERS: | LENDERS: |
| HERCULES CAPITAL, INC. | HERCULES CAPITAL, INC. |
| Signature: | /s/ Seth Meyer |
| Print Name: | Seth Meyer |
| Title: | Chief Financial Officer |
| HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P. | HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P. |
| By: Hercules Adviser LLC, its Investment Adviser | By: Hercules Adviser LLC, its Investment Adviser |
| Signature: | /s/ Seth Meyer |
| Print Name: | Seth Meyer |
| Title: | Authorized Signatory |
| HERCULES PRIVATE CREDIT FUND 1 L.P. | HERCULES PRIVATE CREDIT FUND 1 L.P. |
| By: Hercules Adviser LLC, its Investment Adviser | By: Hercules Adviser LLC, its Investment Adviser |
| Signature: | /s/ Seth Meyer |
| Print Name: | Seth Meyer |
| Title: | Authorized Signatory |

---

[Signature Page to Second Amendment to Loan and Security Agreement]

<u>Exhibit A to Second Amendment Agreement</u>

**EXHIBIT E**

**COMPLIANCE CERTIFICATE**

Hercules Capital, Inc. (as "<u>Agent</u>")<br> 1 North B Street, Suite 2000<br> San Mateo, CA 94401

Reference is made to that certain Loan and Security Agreement dated June 21, 2024 and the Loan Documents (as defined therein) entered into in connection with such Loan and Security Agreement all as may be amended from time to time (hereinafter referred to collectively as the "<u>Loan Agreement</u>") by and among Hercules Capital, Inc. ("<u>Agent</u>"), the several banks and other financial institutions or entities from time to time party thereto (each, a "<u>Lender</u>" and, collectively, "<u>Lenders</u>"), Neuehealth, Inc., a Delaware corporation ("<u>Company</u>"), each other Original Borrower and each Additional Borrower (together with Company and each Original Borrower, individually or collectively, as the context may require, "<u>Borrower</u>"), and each Guarantor from time to time party thereto. All capitalized terms not defined herein shall have the same meaning as defined in the Loan Agreement.

The undersigned is an Officer of Company, knowledgeable of all Company financial matters, and is authorized, on behalf of Company, to provide certification of information regarding Company; hereby certifies, on behalf of Company, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Company is in compliance for the period ending ___________ of all covenants, conditions and terms of the Loan Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) other than as described below (*provided* that the exceptions noted below shall not apply to an earlier date and shall not cure any Default or Event of Default arising from any false or incorrect misrepresentations and warranties previously made),all representations and warranties contained in the Loan Agreement are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) any financial statements delivered with this Compliance Certificate are prepared in accordance with GAAP (except for the absence of footnotes with respect to unaudited financial statements, for the absence of footnotes and subject to normal year-end adjustments and for which monthly statements, do not contain certain non-cash items that are customarily included in quarterly and annual financial statements) and are consistent from one period to the next except as explained below.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;REPORTING REQUIREMENT | &nbsp;&nbsp;REQUIRED | &nbsp;&nbsp;CHECK IF<br> ATTACHED |
| &nbsp;&nbsp;Interim Financial Statements | &nbsp;&nbsp;Monthly within 30 days | &nbsp;&nbsp;[N/A][x] |
| &nbsp;&nbsp;Interim Financial Statements | &nbsp;&nbsp;Quarterly within 45 days | &nbsp;&nbsp;[N/A][x] |
| &nbsp;&nbsp;Joint Venture Company Interim Financial Statements | &nbsp;&nbsp;Quarterly within 45 days | &nbsp;&nbsp;[N/A][x] |
| &nbsp;&nbsp;Audited Financial Statements | &nbsp;&nbsp;FYE within 90 days | &nbsp;&nbsp;[N/A][x] |

---

ACCOUNTS OF LOAN PARTIES AND THEIR SUBSIDIARIES AND AFFILIATES

The undersigned hereby also confirms, on behalf of Company, that the below disclosed accounts represent all depository accounts and securities accounts presently open in the name of each Loan Party or their Subsidiary/Affiliate, as applicable.

Each new account that has been opened since delivery of the previous Compliance Certificate is designated below with a "\*".

Each Excluded Account is designated below with a "\*\*".

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  | &nbsp;&nbsp;**Depository <br> AC #** | &nbsp;&nbsp;**Financial<br> Institution** | &nbsp;&nbsp;**Account <br> Type<br> (Depository /<br> Securities)** | &nbsp;&nbsp;**Last <br> Month<br> Ending <br> Account <br> Balance** | &nbsp;&nbsp;**Purpose of<br> Account** |
| &nbsp;&nbsp;**LOAN PARTY <br> Name/Address:** |  |  |  |  |  |  |
|  | &nbsp;&nbsp;**1** |  |  |  |  |  |
|  | &nbsp;&nbsp;**2** |  |  |  |  |  |
|  | &nbsp;&nbsp;**3** |  |  |  |  |  |
|  | &nbsp;&nbsp;**4** |  |  |  |  |  |
|  | &nbsp;&nbsp;**5** |  |  |  |  |  |
|  | &nbsp;&nbsp;**6** |  |  |  |  |  |
|  | &nbsp;&nbsp;**7** |  |  |  |  |  |
| &nbsp;&nbsp;**SUBSIDIARY <br> Name/Address** |  |  |  |  |  |  |
|  | &nbsp;&nbsp;**1** |  |  |  |  |  |
|  | &nbsp;&nbsp;**2** |  |  |  |  |  |
|  | &nbsp;&nbsp;**3** |  |  |  |  |  |
|  | &nbsp;&nbsp;**4** |  |  |  |  |  |
|  | &nbsp;&nbsp;**5** |  |  |  |  |  |
|  | &nbsp;&nbsp;**6** |  |  |  |  |  |
|  | &nbsp;&nbsp;**7** |  |  |  |  |  |

---

The following disclosures are made in relation to the representations and warranties in the Loan Documents:[ ]

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;<u>Name of Test</u> | &nbsp;&nbsp;<u>Required Level</u> | &nbsp;&nbsp;<u>Actual Level</u> | &nbsp;&nbsp;<u>In Compliance Y/N?</u> |
| &nbsp;&nbsp;Minimum Cash Covenant | &nbsp;&nbsp;See Section 7.21(a) |  |  |
| &nbsp;&nbsp;Minimum Adjusted EBITDA Covenant | &nbsp;&nbsp;See Section 7.21(b) |  |  |
| &nbsp;&nbsp;CMS Obligation Liquidity Milestone Date | &nbsp;&nbsp;Occurred as of June 30, 2026 |  |  |

---

INSURANCE POLICIES OF COMPANY AND ITS SUBSIDIARIES

[with Compliance Certificate delivered with annual statements unless delivered during the previous 12 months] (A) a summary of insurance, showing any changes to the insurance policies required to be maintained in accordance with <u>Section 6.1</u>, and (B), renewal statements (including renewed certificates of insurance) and copies of the insurance policies of Company and its Subsidiaries

---

| |
|:---|
| Very Truly Yours, |
| **NEUEHEALTH, INC.** |
| By: |
| Name: |
| Its: |

---

<u>Exhibit B to Second Amendment Agreement</u>

**<u>SCHEDULE 1.1</u>**

**COMMITMENTS**

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**LENDERS** | **TRANCHE 1<br> COMMITMENT** | **TRANCHE 2<br> COMMITMENT** | **TRANCHE 3<br> COMMITMENT** | **TRANCHE 4<br> COMMITMENT\*** |
| &nbsp;&nbsp;HERCULES CAPITAL, INC. | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] |
| &nbsp;&nbsp;HERCULES PRIVATE GLOBAL VENTURE GROWTH FUND I L.P. | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] |
| &nbsp;&nbsp;HERCULES PRIVATE CREDIT FUND 1 L.P. | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] |
| &nbsp;&nbsp;TOTAL COMMITMENTS | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] | $[\*\*\*] |

---

\* Subject to the terms and conditions of this Agreement (including approval by the Lenders' investment committee(s) in their sole discretion).

## Exhibit 99.1

**Exhibit 99.1**

**NeueHealth Announces Closing of Take-Private Transaction**

**October 2, 2025 – DORAL, Fla.** – NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE: NEUE), the value-driven healthcare company, today announced the successful closing of its previously announced merger under which NeueHealth has been acquired by an affiliate of New Enterprise Associates ("NEA") at an enterprise value of approximately $1.496 billion.

Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered into rollover agreements pursuant to which such stockholders will continue their investments by exchanging their shares of NeueHealth common stock and/or preferred stock for newly issued equity interests in the privately held company. NeueHealth's executive leadership team will continue in their roles upon completion of the transaction and have entered into rollover agreements to roll over 100% of their equity interests for newly issued equity interests in the privately held company.

With the completion of the transaction, the Company's common stock ceased trading on the New York Stock Exchange on October 2, 2025. The Company intends to make the applicable filings with the U.S. Securities and Exchange Commission (the "SEC") to suspend its periodic reporting obligations and to terminate the registration of the Class A Shares underlying the Company's active registration statements.

"Since our founding, NeueHealth has been committed to aligning the interests of consumers, payors, and providers to create a seamless, more coordinated care experience for all," said Mike Mikan, President and CEO of NeueHealth. "This transaction marks a significant milestone for our Company as it allows us the flexibility and resources to continue to fulfill this mission as we advance our value-driven, consumer-centric care model and drive long-term, sustainable growth into the future."

**About NeueHealth**

NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 600,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare system. For more information, visit: www.neuehealth.com.

**About NEA**

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than $28 billion in assets under management as of June 30, 2025 and invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of investing includes 284 portfolio company IPOs and more than 500 mergers and acquisitions. For more information, please visit www.nea.com.

**Forward-Looking Statements**

This release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, and statements as to the expected timing, completion and effects of the transaction. These statements often include words such as "anticipate," "expect," "plan," "believe," "intend," "project," "forecast," "estimates," "projections," "outlook," "ensure," and other similar expressions. These forward-looking statements include any statements regarding our plans, expectations and financial guidance. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: the failure to complete the transaction on the anticipated terms and within the anticipated timeframe, including as a result of failure to obtain required stockholder or regulatory approvals or to satisfy other closing conditions; potential litigation relating to the transaction that could be instituted against NEA, the Company or their respective affiliates, directors, managers, officers or employees, and the effects of any outcomes related thereto; potential adverse reactions or changes to our business relationships or operating results resulting from the announcement, pendency or completion of the transaction; the risk that our stock price may decline significantly if the transaction is not consummated; certain restrictions during the pendency of the transaction that may impact our ability to pursue certain business opportunities or strategic transactions; costs associated with the transaction, which may be significant; the occurrence of events, changes or other circumstances that could give rise to the termination of the merger agreement, including in circumstances requiring us to pay a termination fee; our ability to continue as a going concern; our ability to comply with the terms of our credit facilities or any credit facility into which we enter in the future; our ability to receive the remaining proceeds from the sale of our Medicare Advantage business in California in a timely manner; our ability to obtain any short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down of our remaining Individual and Family Plan ("IFP") and MA businesses, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to the transaction or due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our business offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our care partner's abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage any growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions, integrate acquired businesses, and quickly and efficiently divest businesses as needed; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to mitigate risks associated with our ACO businesses, including any unanticipated market or regulatory developments; and the other factors set forth under the heading "Risk Factors" in the Company's reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.

**Investor Contact:**

IR@neuehealth.com

**Media Contact:**

media@neuehealth.com